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ABSTRAK
Latar belakang: hipoglikemia merupakan efek samping utama dari terapi insulin pada pasien diabetes 
melitus. Penelitian ini dilakukan untuk mengevaluasi kejadian hipoglikemia pada pasien diabetes melitus 
tipe 1 (T1DM) atau diabetes melitus tipe 2 (T2DM) yang diobati dengan insulin pada kohort Indonesia. 
Metode: penelitian kohort Indonesia ini terdiri dari evaluasi retrospektif dan prospektif terhadap episode 
hipoglikemik, dengan menggunakan International Operations Hypoglycemia Assessment Tool (IO HAT) pada 
374 pasien diabetes Indonesia (T1DM; n=17 dan T2DM; n=357). Pasien berusia ≥18 tahun dan diobati dengan 
insulin selama >12 bulan dipilih untuk penelitian ini (ClinicalTrials.gov nomor: NCT02306681). Hasil: sebanyak 
374 pasien disertakan untuk studi ini dan menyelesaikan self assessment questionnaire 1 (SAQ1). Semua pasien 
T1DM (17 [100%]) dan 347 pasien T2DM (97,2%) menyelesaikan SAQ2. Hampir semua pasien dalam 4 minggu 
periode prospektif melaporkan setidaknya satu kejadian hipoglikemi (T1DM 100%, T2DM 99,4%) dan tingkat 
kejadian hipoglikemia adalah 67,5 kejadian per pasien-tahun (PPY) dan 25,7 kejadian PPY masing-masing 
untuk pasien T1DM dan T2DM. Diantara pasien dengan T1DM dan T2DM, 5,9% dan 36,4%, masing-masing, 
tidak mengetahui apa hipoglikemia pada awal penelitian. Tercatat proporsi yang tinggi dari pasien memiliki 
kesadaran yang buruk akan kejadian hipoglikemi (82,4% dan 62,7%, masing-masing). Kesimpulan: secara 
keseluruhan, proporsi yang tinggi dari pasien yang melaporkan kejadian hipoglikemi pada periode prospektif 
mengindikasikan kurang pelaporan selama periode retrospektif karena bias ingatan (recall bias). Oleh karena 
itu dibutuhkan program pendidikan pasien untuk meningkatkan kesadaran akan hipoglikemia dari pasien 
diabetes di Indonesia.
Kata kunci: alat penaksir hipoglikemia operasi internasional, hipoglikemia, pasien dengan diabetes yang 
diobati dengan insulin, observasional, Indonesia.
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ABSTRACT
Background: hypoglycemia is a major adverse event of insulin therapy for diabetes mellitus patients. The 
study was conducted to evaluate the incidence of hypoglycemia among insulin treated patients with type 1 
diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) in the Indonesian cohort. Methods: this Indonesian 
cohort study consisted of retrospective and prospective evaluation of hypoglycemic episodes, using International 
Operations Hypoglycemia Assessment Tool (IO HAT) in 374 patients with diabetes (T1DM; n=17 or T2DM; 
n=357). The patients of ≥18 years of age and treated with insulin for >12 months were selected for this study 
(ClinicalTrials.gov number: NCT02306681). Results: a total of 374 patients were enrolled in this study and 
completed SAQ1. All patients with T1DM (17 [100%]), and 347 (97.2%) patients with T2DM completed SAQ2. 
Almost all the patients in the 4-week prospective period reported at least one hypoglycemic event (T1DM 100%, 
T2DM 99.4%) and the incidence rate of any hypoglycemia was 67.5 events per patient-year (PPY) and 25.7 
events PPY for T1DM and T2DM patients, respectively. Among patients with T1DM and T2DM, 5.9% and 
36.4%, respectively, did not know what hypoglycemia was at baseline, also high proportion of patients had 
impaired hypoglycemic awareness in the study (82.4% and 62.7%, respectively). Conclusion: overall, high 
proportion of patients reported hypoglycemic events in the prospective period indicating under reporting during 
the retrospective period due to recall bias. Therefore, there is a need for patient education program to improve 
the awareness of hypoglycemia in diabetes patient in Indonesia.
Keywords: international operations hypoglycemia assessment tool, hypoglycemia, insulin-treated patients 
with diabetes, observational, Indonesia.
INTRODUCTION
In developing countries,  increased 
urbanization, along with sedentary lifestyle 
and modified diet are the major contributors to 
increased prevalence of diabetes.1,2 By the year 
2040, the cases of diabetes in Indonesia are 
expected to increase to 16.2 million, compared 
to 10 million cases in 2015.3 
Insulin therapy is the standard treatment 
option for Type 1 Diabetes Mellitus (T1DM) 
and Type 2 Diabetes Mellitus (T2DM) 
patients due to progressive nature of disease.4,5 
Hypoglycemia is a major adverse event with 
insulin therapy. Symptoms of hypoglycemia 
range from unpleasant experience to life-
threatening events; leading to patient fear and 
ultimately causing reduced compliance or even 
refusal of insulin treatment and also prevents 
health-care professionals from switching to 
insulin treatment or modifying the insulin dose 
whenever required.6-11 In a study conducted to 
assess the barrier of insulin treatment, 80% of the 
family physicians reported that insulin treatment 
is not commenced due to fear of hypoglycemia.10 
Apart from impacting diabetes management, 
hypoglycemia also increases economic burden 
by impacting work productivity, interfering 
with daily functioning of patients, increasing 
health care utilization, increasing mortality 
risk, and severe hypoglycemia increases risk of 
cardiovascular adverse events and death.7,12,13
DiabCare Asia study published in 2008 
highlighted that despite the availability of clinical 
practice guidelines in the region, large number of 
T2DM patients (68%) still have poor glycemic 
control.14 Treatment guidelines in Indonesia have 
emphasized on the need for patient education, 
diabetes management during Ramadan, and also 
stressed on regular blood glucose monitoring 
in patients who are at high risk of developing 
hypoglycemia.15,16 However, awareness-to-
adherence model study conducted in Indonesia 
has shown that in spite of high awareness of 
guidelines among physicians, adherence to these 
guidelines is really low mainly due to inability to 
access guidelines, physicians’ attitude, and belief 
toward the guidelines.17 This further worsens the 
case as there is not much awareness regarding 
insulin-associated hypoglycemia among patients. 
This shows that data on hypoglycemic rates and 
its impact on economic and social life of patients 
is lacking in the region. There is an unmet need 
for such studies and increased patient education 
program in the region due to perceived risk of 
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hypoglycemia.
The International Operations Hypoglycemia 
Assessment Tool (IO HAT) study was a non-
interventional, real-world, observational 6-month 
retrospective and 4-week prospective study 
of self-reported hypoglycemic events in 7289 
patients with insulin-treated T1DM and T2DM 
from nine countries.18 The aim of the present 
study was to evaluate the hypoglycemic rates in 
insulin-treated Indonesian patients with T1DM 
and T2DM. In addition, impact of hypoglycemia 
on work/study and healthcare, patients’ response 
and patients’ knowledge of hypoglycemia were 
also studied.
METHODS
The IO HAT study was a retrospective and 
prospective observational study to evaluate 
hypoglycemic episodes using a two-part self-
assessment questionnaire (SAQ1 and SAQ2) 
and patient diary (PD) (Figure 1). The current 
study concentrates on the results from Indonesian 
cohort of IO HAT study where insulin-treated 
T1DM and T2DM patients were recruited at 23 
sites between 18 December 2014 and 04 April 
2015 (for further details, please refer the Study 
Center Details at the end of this manuscript). 
The study was conducted in accordance with 
the guidelines for Good Pharmacoepidemiology 
Practices (2007), Declaration of Helsinki (2004), 
the International Conference on Harmonization 
Guidelines for Good Clinical Practice (1996), 
and the study protocol and the assessments 
were approved by country-specific regulatory 
and ethical agencies.19,20 The study material 
was translated to local language and the data 
obtained was back transferred to English for 
analysis purpose.
Study Population
Male or female patients of ≥18 years of age 
with T1DM or T2DM, treated with insulin (e.g. 
pre-mixed, short-acting, and/or long-acting) 
for >12 months and who had given informed 
consent were eligible for this study. Non-
ambulatory, illiterate patients with language 
barrier in understanding the questionnaire were 
excluded from this study. Patients were recruited 
randomly into the study via consecutive sampling 
during routine clinical visit with their healthcare 
provider in Indonesia.
Study Objective
Primary objective was to determine the 
percentage of patients experiencing at least 
one hypoglycemic episode during the 4-week 
prospective observational period.
The secondary objectives were to determine 
Figure 1. IO HAT study design
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the difference in incidence of various types of 
hypoglycemic episodes (e.g. any, nocturnal, 
and severe) between the 4-week retrospective 
period (or 6-month retrospective period for 
severe hypoglycemia) and 4-week prospective 
period, relationship between incidence of 
hypoglycemia and insulin regimen, patient 
knowledge of hypoglycemia, proportion of 
patients with hypoglycemic unawareness, 
fear of hypoglycemia, patients’ response to 
hypoglycemia, and impact of hypoglycemia on 
work/study.
Hypoglycemic Assessments
Severe hypoglycemia is an episode requiring 
assistance of another person to actively administer 
carbohydrate, glucagon, or take other corrective 
actions (as per American Diabetes Association 
[ADA] definition).21 Non-severe hypoglycemia 
is an episode managed by the patient alone. Any 
hypoglycemia is the sum of severe hypoglycemia 
and non-severe hypoglycemia. Nocturnal 
hypoglycemia is hypoglycemia occurring 
between midnight and 06:00 hours.
The incidence of hypoglycemia was captured 
in the SAQ1 and SAQ2 and in the PD. Part 1 was 
used to record baseline demographic, treatment 
information, patient information, hypoglycemic 
unawareness, history of severe hypoglycemia 
over the last 6 months and any and nocturnal 
hypoglycemia over the last 4 weeks. Part 2 was 
used to evaluate the occurrence of all types 
hypoglycemia over 4 weeks after baseline and 
the effect of hypoglycemia on productivity and 
healthcare utilization. To assist patients recall and 
as a reminder to complete SAQ2, patients were 
provided with a PD to capture hypoglycemic 
episodes.
Patient knowledge of hypoglycemia was 
evaluated by checking if the patient’s definition 
of hypoglycemia was consistent with ADA 
hypoglycemia definition, and if there was 
awareness regarding hypoglycemia before 
reading the instructions provided in informed 
consent.22 Hypoglycemic unawareness was 
assessed using SAQ, according to response to 
question: ‘Do you have symptoms when you 
have a low blood sugar?’, if ‘Yes’ denoted 
normal awareness, ‘usually’ denoted impaired 
awareness, and ‘occasionally’ and ‘never’ 
denoted severely impaired awareness.22 Fear of 
hypoglycemia was reported on a scale of 0 to 10 
by the patients, where ‘0’ indicated ‘not afraid 
at all’ and ‘10’ indicated ‘absolutely terrified’.
Data Analysis
The primary endpoint was the percentage of 
patients who experienced at least one episode 
of hypoglycemia calculated together with the 
95% confidence interval (CI). For secondary 
endpoints, the incidence rate (IR) of various type 
of hypoglycemia was calculated as the number 
of events per patient year (PPY) together with 
the 95% CI, computed as total number of events 
divided by total follow-up time in patient years. 
The incidence rate was reported by diabetes type 
(T1DM, T2DM) and insulin regimen used.
All statistical tests were two-sided and 
regarded as exploratory, with statistical 
significance of p <0.05. There were no adjustments 
for multiple comparisons. Continuous and 
categorical data was reported using descriptive 
statistics (as percentage of patients).
RESULTS
A total of 374 patients were enrolled in this 
study and completed SAQ1; of which 17 patients 
were with T1DM and 357 patients were with 
T2DM. All patients with T1DM (17 [100%]) 
and 347 (97.2%) patients with T2DM completed 
SAQ2 and PD. The demographic and baseline 
characteristics were comparable between T1DM 
and T2DM patients, with few exceptions (Table 
1).
Incidence of Hypoglycemia
Any hypoglycemia. During the 4-week 
prospective period, 100% (95%CI: 80.5%, 
100.0%) patients reported hypoglycemic events 
in TIDM group and 99.4% (95%CI: 97.9%, 
99.9%) patients reported hypoglycemic events 
in T2DM group. While during the retrospective 
period, 52.9% (95% CI: 27.8%, 77.0%) patients 
reported hypoglycemic events in T1DM group 
and 39.5% (95% CI: 34.4%, 44.8%) patients 
reported hypoglycemic events in T2DM group. In 
patients with T1DM, the IR of any hypoglycemia 
increased significantly from the retrospective 
period to prospective period (33.0 events PPY 
[95%CI: 23.9%, 44.4%] to 67.5 events PPY 
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[95%CI: 54.2%, 83.2%], respectively; p=0.015) 
(Figure 2 [a]). Similarly, a significant increase 
in incidence rate of any hypoglycemia was 
observed for T2DM patients from retrospective 
period to prospective period (11.2 events PPY 
[95%CI: 9.96%, 12.51%] to 25.7 events PPY 
[95%CI: 23.8%, 27.7%], respectively; p<0.001) 
(Figure 2 [b]).
Nocturnal hypoglycemia. During the 
4-week prospective period, 29.4% (95%CI: 
10.3%, 56.0%) patients reported hypoglycemic 
events in TIDM group and 15.3% (95%CI: 
11.7%, 19.6%) patients reported hypoglycemic 
events in T2DM group. While during the 
retrospective period, 47.1% (95%CI: 23.0%, 
72.2%) patients reported hypoglycemic events in 
T1DM group and 13.4% (95%CI: 10.1%, 17.4%) 
patients reported hypoglycemic events in T2DM 
group. The IR of hypoglycemia was higher in 
retrospective period compared to prospective 
period in T1DM patients, while the IRs were 
comparable in both the periods in T2DM patients 
(Figure 2 [a] and [b]).
Severe hypoglycemia. The proportion 
of T1DM patients with severe hypoglycemia 
was higher in the retrospective period (70.6%; 
[95%CI: 44.0%, 89.7%]) than in the prospective 
period (47.1%; [95%CI: 23.0%, 72.2%]); while 
the IRs increased from the retrospective period 
(3.6 events PPY; [95%CI: 2.4%, 5.2%]) to the 
prospective period (7.7 events PPY; [95%CI: 
3.7%, 14.1%]) (Figure 2 [a]). In T2DM 
group, the proportion of patients with severe 
hypoglycemia was higher in prospective period 
(75.1%; [95%CI: 70.2%, 79.6%]) than in the 
retrospective period (59.0%; [95%CI: 53.7%, 
64.1%]). The IRs also increased significantly 
from retrospective period to prospective period 
(2.7 events PPY [95%CI: 2.4%, 2.9%] to 
13.0 events PPY [95%CI: 11.7%, 14.5%], 
respectively; p-value<0.001) (Figure 2 [b]).
Rates of Hypoglycemia by Insulin Regimen
In T1DM patient group, the estimated IRs 
of any hypoglycemic events in the retrospective 
and prospective periods were highest in patients 
using short-acting insulin plus long-acting 
insulin regimen (Figure 3 [a]). The IRs of any 
hypoglycemic events in T2DM patients were 
almost comparable with no differences among 
Table 1. Baseline characteristics of patients in Indonesian 
cohort
Variables T1DM  (n=17)
T2DM 
(n=357)
Age (years) 31.8 (13.9) 57.9 (10.1)
Male/female (%) 41.2/58.8 45.9/54.1
Duration of diabetes (years) 11.5 (9.3) 11.2 (7.7)
Duration of insulin use 
(years)
8.7 (9.6) 4.0 (3.4)
BMI (kg/m2) 22.4 (3.3) 26.2 (4.3)
HbA1c (mmol/mol) 73.8 (23.4) 71.5 (22.0)
HbA1c (%) 8.9 (2.1) 8.7 (2.0)
FBG (mmol/l) 8.6 (4.2) 9.2 (3.9)
PPG (mmol/l) 9.9 (4.4) 11.3 (4.3)
Oral anti-diabetic 
medications [n (%)]a
 - Alpha-glucosidase 
inhibitors
0 51 (14.3)
 - Metformin 2 (11.8) 96 (26.9)
 - Bile acid sequestrant 0 3 (0.8)
 - Dipeptydyl peptidase IV 0 46 (12.9)
 - Glucagaon-Like 
Peptide-1
0 1 (0.3)




 - None 15 (88.2) 194 (54.3)
 - Missing 0 0
Insulin regimen [n (%)]a
 - Short-acting insulin 0 21 (5.9)
 - Long-acting insulin 0 60 (16.8)
 - Pre-mix 4 (23.5) 107 (30.0)
 - Both short and long 
acting
13 (76.5) 164 (45.9)
 - Both short acting and 
pre-mix
0 1 (0.3)
 - Both long acting and 
pre-mix
0 4 (1.1)
Symptoms of diabetes-related complications, %
 - Tremor 100 86.3
 - Sweating 82.4 69.2
 - Weakness 88.2 68.1
 - Hunger 82.4 66.7
 - Yellow vision 82.4 62.5
Data are mean (SD) unless otherwise stated.
a Percentages based on number of patients with evaluable 
data.
BMI, Body mass index; FBG, fasting blood glucose; 
HbA1c, hemoglobin A1c; N, total number of subjects 
participating; PPG, postprandial glucose; SD, standard 
deviation; SGLT2, Sodium-glucose co-transporter-2; 
T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes 
mellitus.
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different treatment regimens (Figure 3 [b]).
The IR of nocturnal hypoglycemia in patients 
with T1DM was highest in the retrospective 
period and prospective period in patients using 
short-acting insulin plus long-acting insulin 
regimen (14.1 events PPY and 9.0 events PPY, 
respectively) (Figure 3[c]). Similar to any 
hypoglycemia, the IR of nocturnal hypoglycemic 
events in T2DM patients was almost comparable 
with no differences among different treatment 
regimens.
Patient Perspective on Hypoglycemia
At baseline, more patients with T1DM 
(94.1%) than with T2DM (63.6%) knew about 
hypoglycemia before providing the definition in 
SAQ1 (Figure 4).
Among the patients who used blood glucose 
monitoring to determine hypoglycemia, majority 
of patients (94.1%T1DM and 77.6% of T2DM) 
provided consistent values of blood glucose 
measurements as per the standard definitions 
of hypoglycemia (≤3.9 mmol/L or ≤70 mg/dL). 
Patient perspectives, including hypoglycemic 
awareness, fear of hypoglycemia, and response 
to hypoglycemia are described in Table 2.
Most of the patients (82.4% and 67.2% 
patients with T1DM and T2DM, respectively) 
had impaired hypoglycemia awareness. Both 
T1DM and T2DM patients experienced similar 
severity of fear; with a mean (SD) score of 5.1 
(3.17) and 4.1 (2.99), respectively.
Overall, the proportion of patients who took 
actions was greater in T1DM than T2DM group 
in both retrospective and prospective periods 
(Table 2). The proportion of T1DM and T2DM 
patients who increased calorie intake was greater 
in retrospective period (76.5% and 27.5%, 
respectively) than in prospective period (52.9% 
and 21.6%, respectively). Similar results were 
observed for actions such as avoiding physical 
exercise and requiring any form of medical 
assistance.
‘Any’ and ‘Nocturnal’ based on 4-week period for both retrospective and prospective analyses. *Retrospective data based on 
6-month period and prospective data based on 4-week period. RR, rate ratio; T1DM, type 1 diabetes mellitus; T2DM, type 2 
diabetes mellitus.
Figure 2. Incidence of hypoglycemia rates in (a) T1DM and (b) T2DM patients.
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Data based on 4-week period for both retrospective and prospective analyses for any hypoglycemia. Retrospective data based 
on 6-month period and prospective data based on 4-week period for Nocturnal hypoglycemia. S+L, short-acting and long-acting 
insulin; T1DM, type 1 diabetes mellitus; T2DM, type 2 diabetes mellitus.
Figure 3. Rates of hypoglycemia by insulin regimen: (a) Any hypoglycemic events (T1DM), (b) Any hypoglycemic events 
(T2DM), and (c) Nocturnal hypoglycemic events (T1DM).
Figure 4. Patient perspective on hypoglycemia.
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Table 2. Patient perspectives on hypoglycemia
Variables T1DM (N=17) T2DM (N=357)
Knew what hypoglycemia was at baseline before SAQ1 [n/N 
total (%)]a 16/17 (94.1) 225/354 (63.6)
Hypoglycemia awareness (%)
 - Normal 17.6 13.7
 - Impaired 82.4 67.2
 - Severely impaired 0 13.7
Fear of hypoglycemia (scale of 0 to 10; %)a
 - 0 = no fear 5.9 14.6
 - 1 11.8 9.0
 - 2 5.9 9.8
 - 3 5.9 14.8
 - 4 11.8 9.0
 - 5 23.5 14.0
 - 6 5.9 5.9
 - 7 5.9 7.6
 - 8 5.9 5.6
 - 9 0 2.2
 - 10 = absolutely terrified 17.6 7.6







 - Events requiring hospital admission 11.8 0 6.2 0.6
 - Attended additional clinical appointments 0 5.9 1.9 1.7
 - Made additional telephone contacts 0 11.8 2.9 2.9
Patient response to hypoglycemia (%)a
 - Consulted their doctor/nurse 52.9 58.8 34.7 21.0
 - Required any form of medical assistance 64.7 58.8 38.9 21.3
 - Increased calorie intake 76.5 52.9 27.5 21.6
 - Avoided physical exercise 35.3 41.2 14.6 9.5
 - Reduced insulin dose 29.4 35.3 18.2 12.4
 - Skipped insulin injections 17.6 11.8 6.4 7.5
Increased blood glucose monitoring 29.4 52.9 17.9 14.1
N, total number of subjects participating; n, number of subjects who responded to the set of questions; a Percentages based 
on number of patients with evaluable data. SAQ1, self-assessment questionnaire part 1; T1DM, type 1 diabetes mellitus; 
T2DM, type 2 diabetes mellitus
Impact of Hypoglycemic Events on Work 
and Study
Overall the proportion of patients with 
T1DM and T2DM, who had taken leave from 
work, arrived late to work, or left early from 
work due to hypoglycemic events was lesser in 
prospective period than in retrospective period.
In retrospective period, 9 of 17 T1DM 
patients and 107 of 357 T2DM patients were 
either studying or were part-time or full-time 
employee. Out of those, three (33.3%) T1DM 
patients had taken leave from work and left early 
from work or study in each category and two 
(22.2%) arrived late for work or study. In the 
prospective period, one (11.1%) T1DM patient 
arrived late and left early from work or study 
in each category. In T2DM patient group, ten 
(9.3%), nine (8.4%), and eight (7.5%) patients 
had taken leave, left early, and arrived late to 
work or study respectively, in the retrospective 
period, while five (4.9%) had taken leave and 
three (2.9%) each had left early and arrived late 
to work or study, in the prospective period.
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Impact of Hypoglycemic Events on the 
Medical System
In T1DM patient group, 11.8% of patients 
required hospital admission in the retrospective 
period, while in the prospective period. None of 
the T1DM patients required hospital admission 
due to hypoglycemic events, while 11.8% of 
patients made additional telephone contacts 
and 5.9% of patients took additional clinical 
appointments. In T2DM patient group, similar 
proportion of patients made additional telephone 
contacts (2.9% in both) and took additional 
clinical appointments (1.9% and 1.7%) in both 
retrospective period and prospective period 
respectively. The proportion of patients who 
required hospital admission was higher in 
retrospective period compared to prospective 
period (6.2% vs 0.6%, respectively).
DISCUSSION
This study describes results from Indonesia 
cohort of the multicenter, international, 6 month 
retrospective and 4-week prospective study using 
a two-part SAQ to investigate the prevalence 
of hypoglycemia in insulin-treated adults with 
T1DM or T2DM. This is the first patient-reported 
observational study to assess hypoglycemia in 
Indonesia.
Almost all the patients in the prospective 
period reported at least one hypoglycemic event 
(T1DM: 100%, T2DM: 99.4%). The lesser 
proportion of patients reporting hypoglycemia 
in the retrospective period could be attributed 
to patient recall bias as SAQs were used to 
record data; in prospective period, PDs were 
additionally used to improve recall. In contrast, 
the proportion of patients reporting nocturnal 
hypoglycemia was either comparable or more in 
the retrospective period than in the prospective 
period. This could have been possible as the 
patients had clear definition of nocturnal 
hypoglycemia in the prospective period and 
hence reported only those events which occurred 
during this period. Moreover, the PDs which 
were used to record events in prospective period 
can be difficult to fill at night probably resulting 
in under-reporting of nocturnal hypoglycemia.
In addition, impact of nocturnal hypoglycemia 
may have resulted in increased reporting of 
nocturnal hypoglycemia in the retrospective 
period when patients were asked to recall. The 
incidence of any hypoglycemia was significantly 
higher in the prospective period compared to 
retrospective period in both T1DM and T2DM 
patients (T1DM: 33.0 vs. 67.5 events PPY, 
p=0.015; T2DM: 11.2 vs. 25.7 PPY, p<0.001). 
The higher incidence in the prospective period 
may be due to the fact that SAQs and PDs 
acted as a learning tool and reinforce patients’ 
knowledge resulting in increased hypoglycemic 
awareness.
Similarly, severe hypoglycemia was also 
reported with higher proportion in the prospective 
period compared to the retrospective period for 
T2DM patients. In this case, recall bias was more 
pronounced as retrospective data was based on 
6 month period in contrast to 4 week period for 
any or nocturnal hypoglycemia.
Overall, the incidence of any hypoglycemia 
(11.2 to 67.5 events PPY) and severe 
hypoglycemia (7.7 to 13.0 events PPY) in 
this sub-study was found to be higher than the 
previously reported studies.23,24 A systematic 
review and meta-analysis study by Edridge et 
al23 had reported that IR of mild hypoglycemia 
was 19 events per patient year and IR of severe 
hypoglycemia was just 0.80 events per patient 
year in T2DM patients. An observational 
study in United States where hypoglycemic 
events were identified by claim showed that 
the overall incidence of hypoglycemia was 
just 3.46/100 patient years.24 The incidence of 
severe hypoglycemia in Hypos-1 study in T1DM 
patients was found to be 0.49 events/patient 
years.25 There are no previous clinical trials or 
observational studies in this region to compare the 
results of this sub-analysis. Nevertheless, higher 
IRs of hypoglycemia in this region emphasize 
on the need for patient education and regular 
blood glucose monitoring in diabetic patients 
with insulin therapy. The guidelines on proper 
diabetes management should be made available 
to all healthcare professionals in the region and 
should focus on use of insulin regimens and 
newer treatment options which have low risk of 
hypoglycemia.26-28 In T1DM patients, the IRs of 
any and nocturnal hypoglycemia were highest 
in patients receiving short- plus long-acting 
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insulin regimens during the retrospective and 
prospective periods, while in T2DM the IRs of 
hypoglycemia were independent of the type of 
insulin regimen used and were in general higher 
in the prospective period than in the retrospective 
period.
In general, 35% of patients did not know 
what hypoglycemia was at baseline. Only 
29.9% and 18.2% of the overall patients defined 
hypoglycemia by symptoms only and by both 
symptoms and blood glucose measurements, 
respectively. Majority of the patients reported 
occasional symptoms of hypoglycemia during 
low blood glucose measurements indicating 
impaired hypoglycemia awareness. This 
indicates the need of patient education on the 
importance of blood glucose monitoring, risks 
associated with hypoglycemia and symptoms of 
hypoglycemia to create awareness in the region.
Hypoglycemia has an impact on quality 
of life (QoL) such as work and study and also 
impacts healthcare utilization. The impact of 
hypoglycemia on the work life was lesser in the 
prospective period than in retrospective period. 
This suggests that study tools (SAQ and PDs) 
may have played some role in hypoglycemia 
management in this period and therefore 
improving QoL of patients’. A study by Pranoto 
et al29 which were conducted to assess the safety 
of insulin when administered by primary health 
care providers in Indonesia concluded that 
there were minimal hypoglycemic events noted 
with early initiation of insulin therapy and all 
of them were mild without requiring hospital 
admission. Self-monitoring of blood glucose 
examination done in the study indicated that by 
creating awareness for use of insulin therapy 
among healthcare, providers will help in proper 
management of diabetic patients in the region.
CONCLUSION
The high incidence of hypoglycemia in 
almost all patients reporting events during the 
prospective period may indicate under-reporting 
of hypoglycemia during the retrospective period 
due to recall bias. The influence of patient 
education during the study leading to increased 
hypoglycemia knowledge and therefore higher 
reporting during the prospective period was also 
one of the contributing factors. The successful 
management of diabetes is to achieve targeted 
glycemic control, while minimizing patient 
risk of hypoglycemia through appropriate 
monitoring and creating sufficient awareness 
about hypoglycemia. There is an unmet need 
for better education including the importance 
of self-monitoring of blood glucose, creating 
sufficient awareness by minimizing the fear of 
hypoglycemia, and need for newer treatment 
options with low risk of hypoglycemic profile.
STUDY CENTRES DETAILS
Sahid Sahirman Memorial Hospital, Jakarta 
(1 investigator, 9 study subjects); Fatmawati 
Hospital, Jakarta (1 investigator, 57 study 
subjects); Mitra Keluarga Hospital, Bekasi (1 
investigator, 50 study subjects); Jakarta Medical 
Center Hospital, Jakarta (1 investigator, 10 study 
subjects); Gatot Soebroto Hospital, Jakarta (1 
investigator, 20 study subjects); Siloam Hospital, 
Surabaya (1 investigator, 30 study subjects); Ulin 
Hospital, Banjarmasin (2 investigators, 30 study 
subjects); Ratu Zalecha Hospital, Banjarmasin (1 
investigator, 7 study subjects); Sanglah Hospital, 
Denpasar (3 investigators, 16 study subjects); 
M. Djamil Hospital, Padang (2 investigators, 
22 study subjects); Hasan Sadikin Hospital, 
Bandung (3 investigators, 33 study subjects); 
Saiful Anwar Hospital, Malang (3 investigators, 
45 study subjects); R.D. Kandou Hospital, 
Manado (3 investigators, 45 study subjects).
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